Skip to main content
    S

    Sanara Medtech Inc (SMTI)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $32.76
    +0.41 (+1.27%)

    Market Cap: $297.06M

    Last updated: Nov 17, 2026 at 11:02 AM ET

    Sanara Medtech Inc (SMTI) Earnings: Report Dates and Results

    Updated Nov 11, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Sanara Medtech (SMTI) is expected to report earnings on Mar 22, 2027. In the quarter ended Sep 30, 2026, Sanara Medtech reported EPS of $0.12, above the $0.06 estimate. It beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    36%(8/22)
    Avg Surprise
    -32.93%
    Streak
    2 Q

    Upcoming Estimates

    Reports Mar 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.14
    Range$0.11 - $0.19
    5 analysts
    Revenue Consensus
    $31.31M
    Range$28.42M - $33.49M
    5 analysts
    Reports May 10, 2027 (est.)Period ending Mar 31, 2027
    EPS ConsensusN/A
    RangeN/A
    Revenue Consensus
    N/A
    RangeN/A
    0 analysts

    Next Report

    SMTI has an expected report date of Mar 22, 2027.

    SMTI Earnings Call

    The latest SMTI earnings call transcript on file is labeled 2026Q1.

    Read the 2026Q1 transcript

    Earnings History

    Of the 22 quarters below that had an estimate, SMTI beat 8, missed 12 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $28.43M, up 8.0% from $26.33M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.12$0.06N/A+100.00%BeatN/A10 up, 0 downNov 11, 2026$28.43M
    Jun 30, 2026$0.05$0.02N/A+150.00%BeatN/A10 up, 0 downAug 11, 2026$28.14M
    Mar 31, 2026$0.04$0.33N/A-87.69%MissN/A10 up, 0 downMay 11, 2026$27.80M
    Dec 31, 2025-$0.19$0.11$0.11 - $0.11-272.73%MissN/A10 up, 0 downMar 24, 2026$27.52M
    Sep 30, 2025-$3.52-$0.21-$0.24 - -$0.19N/AN/AN/A22 up, 0 downNov 12, 2025$26.33M
    Jun 30, 2025-$0.23-$0.44-$0.55 - -$0.33+47.73%BeatN/A21 up, 1 downAug 13, 2025$25.80M
    Mar 31, 2025-$0.41-$0.50N/A+18.00%BeatN/AN/A0 up, 0 downMay 14, 2025$23.43M
    Dec 31, 2024-$0.18-$0.12N/A-56.52%MissN/AN/A0 up, 0 downMar 25, 2025$26.31M
    Sep 30, 2024-$0.34-$0.62-$0.62 - -$0.62+45.16%BeatN/A10 up, 0 downNov 12, 2024$21.67M
    Jun 30, 2024-$0.41-$0.21-$0.21 - -$0.21-95.24%MissN/A10 up, 0 downAug 12, 2024$20.16M
    Mar 31, 2024-$0.21-$0.07-$0.07 - -$0.07-200.00%MissN/A10 up, 0 downMay 13, 2024$18.54M
    Dec 31, 2023-$0.03-$0.13-$0.13 - -$0.13+76.92%BeatN/A10 up, 0 downMar 25, 2024$17.69M
    Sep 30, 2023-$0.13-$0.04N/A-225.00%MissN/A10 up, 0 downNov 13, 2023$16.02M
    Jun 30, 2023-$0.22-$0.13-$0.13 - -$0.13-69.23%MissN/A10 up, 0 downAug 14, 2023$15.75M
    Mar 31, 2023-$0.14-$0.33-$0.33 - -$0.33+57.58%BeatN/A10 up, 0 downMay 15, 2023$15.52M
    Dec 31, 2022-$0.38-$0.26-$0.26 - -$0.26-46.15%MissN/A10 up, 0 downMar 20, 2023$15.32M
    Sep 30, 2022-$0.18-$0.32-$0.32 - -$0.32+43.75%BeatN/A10 up, 0 downNov 14, 2022$13.04M
    Jun 30, 2022-$0.42-$0.28-$0.28 - -$0.28-50.00%MissN/A10 up, 0 downAug 15, 2022$9.67M
    Mar 31, 2022-$0.41-$0.41N/A0.00%In lineN/AN/A0 up, 0 downMay 16, 2022$7.81M
    Dec 31, 2021-$0.48-$0.27-$0.27 - -$0.27-77.78%MissN/A10 up, 0 downMar 30, 2022$7.03M
    Sep 30, 2021-$0.27-$0.18-$0.18 - -$0.18-50.00%MissN/A1N/ANov 12, 2021$5.82M
    Jun 30, 2021-$0.16-$0.12N/A-33.33%MissN/AN/AN/AAug 16, 2021$6.28M
    Mar 31, 2021-$0.17-$0.17N/A0.00%In lineN/AN/AN/AMay 17, 2021$5.01M
    Dec 31, 2020-$0.04N/AN/AN/AN/AN/AN/AN/AMar 30, 2021$4.79M
    Sep 30, 2020-$0.18N/AN/AN/AN/AN/AN/AN/ANov 13, 2020$4.31M
    Jun 30, 2020-$0.18N/AN/AN/AN/AN/AN/AN/AAug 13, 2020$2.97M
    Mar 31, 2020-$0.39N/AN/AN/AN/AN/AN/AN/AMay 12, 2020$3.52M
    Dec 31, 2019-$0.44N/AN/AN/AN/AN/AN/AN/AMar 26, 2020$3.35M
    Sep 30, 2019-$0.35N/AN/AN/AN/A-480.0%N/AN/ANov 14, 2019$2.91M
    Jun 30, 2019-$0.15N/AN/AN/AN/A-1600.0%N/AN/AAug 14, 2019$3.02M
    Mar 31, 2019-$0.39N/AN/AN/AN/A-4000.0%N/AN/AApr 1, 2019$2.49M
    Dec 31, 2018-$0.07N/AN/AN/AN/A-271.8%N/AN/AMar 31, 2019$47537
    Sep 30, 2018$0.09N/AN/AN/AN/A+121.4%N/AN/ANov 14, 2018$1.57M
    Jun 30, 2018$0.01N/AN/AN/AN/AN/AN/AN/AAug 13, 2018$2.26M
    Mar 31, 2018$0.01N/AN/AN/AN/A-67.2%N/AN/AMay 15, 2018$1.96M
    Dec 31, 2017$0.04N/AN/AN/AN/A+107.3%N/AN/AMar 29, 2018$1.70M
    Sep 30, 2017$0.04N/AN/AN/AN/AN/AN/AN/ANov 16, 2017$1.55M
    Jun 30, 2017-$0.08N/AN/AN/AN/A-250.2%N/AN/AAug 14, 2017$1.45M
    Mar 31, 2017$0.03N/AN/AN/AN/AN/AN/AN/AApr 4, 2017$1.61M
    Dec 31, 2016$0.02N/AN/AN/AN/A+22.9%N/AN/AMar 31, 2017$1.75M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$4.35, after -$1.14 the year before. It was -$0.93 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$4.35N/A
    Dec 31, 2024-$1.14N/A
    Dec 31, 2023-$0.52N/A
    Dec 31, 2022-$1.39N/A
    Dec 31, 2021-$1.08N/A
    Dec 31, 2020-$0.79N/A
    Dec 31, 2019-$1.33-3164.5%
    Dec 31, 2018$0.04N/A
    Dec 31, 2017$0.03N/A
    Dec 31, 2016-$0.93N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 2,800 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q1Mar 31, 20262,8126
    2025Q4Dec 31, 20254,5754
    2025Q3Sep 30, 20254,6886
    2025Q2Jun 30, 20254,5407
    2025Q1Mar 31, 20253,4977
    2024Q3Sep 30, 20243,9459
    2024Q2Jun 30, 20244,48712

    2026Q1 Earnings Call

    Opening remarks

    Seth Yon Chief Executive Officer Thank you, operator, and welcome, everyone, to our first quarter 2026 earnings conference call. This was a strong quarter for us, which exceeded our expectations. Q1 2026 was the first full quarter in which we were entirely focused on the surgical market, and the results reflect our sharpened focus and enhanced financial model. We delivered 19% revenue growth compared to the first quarter of 2025, margin improvement and broke through to GAAP net profitability with net income from continuing operations of $0.4 million or $0.04 per diluted share. Our first quarter revenue growth was largely supported by increased sales of our soft tissue repair products, including CellerateRX and BIASURGE. Demand for our products is strong, and we're particularly pleased with our first quarter results given that our first quarter is historically our seasonally slowest sales period of the year. The quarter was also impacted by a three-day related shutdown in January, which caused us to lose three days of shipping during this period. Despite these challenges, we closed out the first quarter with the strongest sales month in company history in March, excluding October of 2024, which benefited from approximately $1.8 million of BIASURGE sales due to the industry disruption caused by Hurricane Helene. During the end of 2025 and continuing into 2026, we began strengthening our sales team to support enhanced net revenue growth and our heightened focus on the surgical market. At quarter end, we had grown our sales team to a total of 43 reps. In addition to strengthening our sales team, we're also very well positioned with a robust surgeon user network, a growing number of hospitals where our products are contracted or approved to be sold, a growing number of facilities where our products were sold during the quarter and a leading distributor network for our products that continues to expand. Let me dig into that a bit. As of quarter end, our products were contracted or approved to be sold in over 4,000 hospitals and ambulatory surgery centers throughout the United States. Our products were sold in over 1,400 facilities throughout the United States, up from more than 1,300 in the first quarter of last year. And we had agreements with more than 450 distributors compared to 400 at this time last year. Also, while it's not our practice to disclose specifics related to our active surgeon user base, I'm pleased to share that we saw solid growth in the number of surgeon users on a year-over-year basis in Q1. While most of you know this, I want to reiterate that Sanara is not subject to reimbursement risk, given we are 100% focused on the surgical setting.

    Frequently Asked Questions About SMTI

    When is Sanara Medtech's next earnings date?

    Sanara Medtech's next earnings report is expected for Mar 22, 2027.

    Did SMTI beat earnings estimates last quarter?

    Yes. Sanara Medtech reported EPS of $0.12 for the quarter ended Sep 30, 2026, above the $0.06 estimate, a 100.00% surprise.

    What EPS do analysts expect from SMTI next quarter?

    The consensus EPS estimate for Sanara Medtech for the quarter ending Dec 31, 2026 is $0.14 from 5 analysts, with estimates from $0.11 to $0.19.

    How often does SMTI beat earnings estimates?

    Sanara Medtech beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate, with an average surprise of -7.01%.